Madrigal Pharmaceuticals Statistics Share Statistics Madrigal Pharmaceuticals has 22.29M
shares outstanding. The number of shares has increased by 2.26%
in one year.
Shares Outstanding 22.29M Shares Change (YoY) 2.26% Shares Change (QoQ) 0.56% Owned by Institutions (%) 99.99% Shares Floating 20.16M Failed to Deliver (FTD) Shares 6,051 FTD / Avg. Volume 1.74%
Short Selling Information The latest short interest is 3.79M, so 17.06% of the outstanding
shares have been sold short.
Short Interest 3.79M Short % of Shares Out 17.06% Short % of Float 19.77% Short Ratio (days to cover) 16.04
Valuation Ratios The PE ratio is -14.09 and the forward
PE ratio is 63.76.
Madrigal Pharmaceuticals's PEG ratio is
-1.47.
PE Ratio -14.09 Forward PE 63.76 PS Ratio 36.44 Forward PS 5.6 PB Ratio 8.7 P/FCF Ratio -14.36 PEG Ratio -1.47
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Madrigal Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.1,
with a Debt / Equity ratio of 0.16.
Current Ratio 6.1 Quick Ratio 5.9 Debt / Equity 0.16 Debt / EBITDA -0.27 Debt / FCF -0.26 Interest Coverage -33.94
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $341.16K Profits Per Employee $-882.37K Employee Count 528 Asset Turnover 0.17 Inventory Turnover 0.18
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 44.34% in the
last 52 weeks. The beta is -1.03, so Madrigal Pharmaceuticals's
price volatility has been lower than the market average.
Beta -1.03 52-Week Price Change 44.34% 50-Day Moving Average 300.95 200-Day Moving Average 309.99 Relative Strength Index (RSI) 66.79 Average Volume (20 Days) 347,235
Income Statement In the last 12 months, Madrigal Pharmaceuticals had revenue of 180.13M
and earned -465.89M
in profits. Earnings per share was -21.9.
Revenue 180.13M Gross Profit 173.9M Operating Income -497.88M Net Income -465.89M EBITDA -450.13M EBIT -451.22M Earnings Per Share (EPS) -21.9
Full Income Statement Balance Sheet The company has 100.02M in cash and 119.57M in
debt, giving a net cash position of -19.55M.
Cash & Cash Equivalents 100.02M Total Debt 119.57M Net Cash -19.55M Retained Earnings -1.8B Total Assets 1.02B Working Capital 806.85M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -455.57M
and capital expenditures -1.46M, giving a free cash flow of -457.03M.
Operating Cash Flow -455.57M Capital Expenditures -1.46M Free Cash Flow -457.03M FCF Per Share -21.48
Full Cash Flow Statement Margins Gross margin is 96.54%, with operating and profit margins of -276.39% and -258.64%.
Gross Margin 96.54% Operating Margin -276.39% Pretax Margin -258.64% Profit Margin -258.64% EBITDA Margin -249.88% EBIT Margin -276.39% FCF Margin -253.72%
Dividends & Yields MDGL does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for MDGL is $450.5,
which is 28.9% higher than the current price. The consensus rating is "Strong Buy".
Price Target $450.5 Price Target Difference 28.9% Analyst Consensus Strong Buy Analyst Count 8
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 25, 2016. It was a
backward
split with a ratio of 1:35.
Last Split Date Jul 25, 2016 Split Type backward Split Ratio 1:35
Scores Altman Z-Score 12.42 Piotroski F-Score 2
